Amicogen Inc (092040) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amicogen Inc (092040) has a cash flow conversion efficiency ratio of -0.027x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.58 Billion ≈ $-2.43 Million USD) by net assets (₩133.35 Billion ≈ $90.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Amicogen Inc to measure how many days the company can operate on defensive assets alone.
Amicogen Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Amicogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Amicogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amicogen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SMAIO SA
PA:ALSMA
|
0.051x |
|
Donkeyrepublic Holding AS
CO:DONKEY
|
0.022x |
|
PEDEVCO Corp
NYSE MKT:PED
|
0.064x |
|
Primotec Group Ltd
TA:PRMG
|
0.071x |
|
Dongbang Agro
KO:007590
|
0.011x |
|
Adveritas Ltd
AU:AV1
|
-1.106x |
|
Kuk Dong
KO:005320
|
-0.103x |
|
Atakule Gayrimenkul Yatirim Ortakligi AS
IS:AGYO
|
0.006x |
Annual Cash Flow Conversion Efficiency for Amicogen Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Amicogen Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Amicogen Inc (092040) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩95.86 Billion ≈ $64.96 Million |
₩-24.42 Billion ≈ $-16.55 Million |
-0.255x | -134.05% |
| 2024-12-31 | ₩122.50 Billion ≈ $83.01 Million |
₩-13.34 Billion ≈ $-9.04 Million |
-0.109x | -375.82% |
| 2023-12-31 | ₩218.97 Billion ≈ $148.40 Million |
₩8.64 Billion ≈ $5.86 Million |
0.039x | +123.21% |
| 2022-12-31 | ₩131.80 Billion ≈ $89.32 Million |
₩-22.41 Billion ≈ $-15.19 Million |
-0.170x | -492.13% |
| 2021-12-31 | ₩186.16 Billion ≈ $126.16 Million |
₩8.07 Billion ≈ $5.47 Million |
0.043x | -25.19% |
| 2020-12-31 | ₩152.94 Billion ≈ $103.65 Million |
₩8.87 Billion ≈ $6.01 Million |
0.058x | -19.24% |
| 2019-12-31 | ₩122.05 Billion ≈ $82.71 Million |
₩8.76 Billion ≈ $5.94 Million |
0.072x | +221.69% |
| 2018-12-31 | ₩127.28 Billion ≈ $86.26 Million |
₩2.84 Billion ≈ $1.92 Million |
0.022x | -83.25% |
| 2017-12-31 | ₩89.19 Billion ≈ $60.44 Million |
₩11.88 Billion ≈ $8.05 Million |
0.133x | -3.68% |
| 2016-12-31 | ₩81.54 Billion ≈ $55.26 Million |
₩11.28 Billion ≈ $7.64 Million |
0.138x | -8.00% |
| 2015-12-31 | ₩82.10 Billion ≈ $55.64 Million |
₩12.34 Billion ≈ $8.36 Million |
0.150x | +69.90% |
| 2014-12-31 | ₩50.02 Billion ≈ $33.90 Million |
₩4.43 Billion ≈ $3.00 Million |
0.088x | -- |
About Amicogen Inc
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company o… Read more